Immunogenicity and reactogenicity of COVID-19 Pfizer-BioNTech (BNT162b2) mRNA vaccination in immunocompromised adolescents and young adults: a systematic review and meta-analyses.
暂无分享,去创建一个
C. Wiysonge | A. Ayuk | Amanda Brand | L. Byamungu | G. Gray | P. Katoto | J. Tamuzi | M. A. Kakubu
[1] S. Sivasampu,et al. Risk of serious adverse events after the BNT162b2, CoronaVac, and ChAdOx1 vaccines in Malaysia: A self-controlled case series study , 2022, Vaccine.
[2] T. Puthanakit,et al. Immunogenicity and Reactogenicity of mRNA BNT162b2 COVID-19 Vaccine among Thai Adolescents with Chronic Diseases , 2022, Vaccines.
[3] Vasiliki Efthymiou,et al. Immunogenicity of the COVID-19 BNT162b2 vaccine in adolescents and young adults with cystic fibrosis , 2022, Journal of Cystic Fibrosis.
[4] William F. Fadel,et al. Effectiveness of COVID-19 Pfizer-BioNTech BNT162b2 mRNA Vaccination in Preventing COVID-19–Associated Emergency Department and Urgent Care Encounters and Hospitalizations Among Nonimmunocompromised Children and Adolescents Aged 5–17 Years — VISION Network, 10 States, April 2021–January 2022 , 2022, MMWR. Morbidity and mortality weekly report.
[5] G. Shefer,et al. Safety and immunogenicity of BNT162b2 mRNA COVID-19 vaccine in adolescents with rheumatic diseases treated with immunomodulatory medications , 2022, Rheumatology.
[6] B. Piccini,et al. COVID‐19 vaccination in adolescents and young adults with type 1 diabetes: Glycemic control and side effects , 2022, Pediatric diabetes.
[7] P. Palma,et al. Safety and Long-Term Immunogenicity of BNT162b2 Vaccine in Individuals with Down Syndrome , 2022, Journal of clinical medicine.
[8] P. Dormitzer,et al. A randomized study to evaluate safety and immunogenicity of the BNT162b2 COVID-19 vaccine in healthy Japanese adults , 2021, Nature Communications.
[9] E. Ingulli,et al. Immunologic response of mRNA SARS-CoV-2 vaccination in adolescent kidney transplant recipients , 2021, Pediatric Nephrology.
[10] S. Hober,et al. Safety and efficacy of the mRNA BNT162b2 vaccine against SARS-CoV-2 in five groups of immunocompromised patients and healthy controls in a prospective open-label clinical trial , 2021, EBioMedicine.
[11] M. Tsolia,et al. Safety and tolerability of the COVID‐19 messenger RNA vaccine in adolescents with juvenile idiopathic arthritis treated with tumor necrosis factor inhibitors , 2021, Arthritis & rheumatology.
[12] K. Syrigos,et al. Comparative Immunogenicity of BNT162b2 mRNA Vaccine with Natural SARS-CoV-2 Infection , 2021, Vaccines.
[13] A. Finn,et al. Initial experience of the safety and tolerability of the BNT162b2 (Pfizer-Bio-N-Tech) vaccine in extremely vulnerable children aged 12–15 years , 2021, Archives of disease in childhood.
[14] J. Gargano,et al. Use of mRNA COVID-19 Vaccine After Reports of Myocarditis Among Vaccine Recipients: Update from the Advisory Committee on Immunization Practices — United States, June 2021 , 2021, MMWR. Morbidity and mortality weekly report.
[15] S. Gupta,et al. Safety of administration of BNT162b2 mRNA (Pfizer‐BioNTech) COVID‐19 vaccine in youths and young adults with a history of acute lymphoblastic leukemia and allergy to PEG‐asparaginase , 2021, Pediatric blood & cancer.
[16] X. de Lamballerie,et al. The BNT162b2 mRNA COVID-19 vaccine in adolescents and young adults with cancer: A monocentric experience , 2021, European Journal of Cancer.
[17] A. Huppert,et al. Immunogenicity and safety of the BNT162b2 mRNA COVID-19 vaccine in people living with HIV-1 , 2021, Clinical Microbiology and Infection.
[18] Manish M Patel,et al. Influenza vaccine effectiveness against hospitalization in the United States, 2019-2020. , 2020, The Journal of infectious diseases.
[19] R. Schmidt-Ott,et al. Vaccination of special populations: Protecting the vulnerable. , 2016, Vaccine.
[20] M. Hernán,et al. ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions , 2016, British Medical Journal.
[21] Tiejun Tong,et al. Optimally estimating the sample mean from the sample size, median, mid-range, and/or mid-quartile range , 2015, Statistical methods in medical research.
[22] J. Sterne,et al. The Cochrane Collaboration’s tool for assessing risk of bias in randomised trials , 2011, BMJ : British Medical Journal.
[23] OUP accepted manuscript , 2022, Rheumatology.